Cohance Lifesciences today announced two proposed transactions to strengthen its Antibody-drug Conjugate (ADC) strategy: an additional investment of USD 13 million in NJ Bio and a controlling investment of USD 5 million in Aruka Bio. Both the transactions will be funded through internal accruals.
Market Samachar is a news aggregator. This article was originally published by Share Market Today. Tap the button above to read the full story on their site.